Myelodysplastic Syndromes
March 2022 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?
Authors:Wang C, Sallman DA
Institution:Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Journal:Cancer J. 2022 Jan-Feb 01;28(1):51-61. doi: 10.1097/PPO.0000000000000569.

2:How low risk are low risk myelodysplastic syndromes?
Authors:DeZern AE, Dalton WB
Institution:Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Journal:Expert Rev Hematol. 2022 Jan;15(1):15-24. doi: 10.1080/17474086.2022.2029698. Epub 2022 Jan 24.

3:Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Authors:Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman MS, Wei X, Raymon H, Sriraman P, Kopytek S, Bewersdorf JP, Burgess MR, Hege K, Stock W
Institution:Department of Internal Medicine, Yale University and Yale Cancer Center, New Haven, CT, USA. amer.zeidan@yale.edu. University of Chicago Medicine, Chicago, IL, USA.
Journal:Ann Hematol. 2022 Mar;101(3):557-569. doi: 10.1007/s00277-021-04734-2. Epub 2022 Jan 4.

4:Red blood cell transfusion in myelodysplastic syndromes: A systematic review.
Authors:Kaka S, Jahangirnia A, Beauregard N, Davis A, Tinmouth A, Chin-Yee N
Institution:Faculty of Medicine, University of Ottawa/The Ottawa Hospital, Ottawa, Ontario, Canada. University of Toronto, Toronto, Ontario, Canada.
Journal:Transfus Med. 2022 Feb;32(1):3-23. doi: 10.1111/tme.12841. Epub 2021 Dec 19.

5:It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS.
Authors:Aguirre LE, Komrokji R, Padron E
Institution:H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address: eric.padron@moffitt.org.
Journal:Best Pract Res Clin Haematol. 2021 Dec;34(4):101325. doi: 10.1016/j.beha.2021.101325. Epub 2021 Oct 23.

6:How do molecular aberrations guide therapy in MDS?
Authors:Bejar R
Institution:UC San Diego Moores Cancer Center, 3855 Health Sciences Drive, San Diego, CA, 92093, USA. Electronic address: rabejar@ucsd.edu.
Journal:Best Pract Res Clin Haematol. 2021 Dec;34(4):101324. doi: 10.1016/j.beha.2021.101324. Epub 2021 Oct 23.

7:Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.
Authors:Henry DH, Glaspy J, Harrup R, Mittelman M, Zhou A, Carraway HE, Bradley C, Saha G, Modelska K, Bartels P, Leong R, Yu KP
Institution:Pennsylvania Hospital, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FibroGen Inc, San Francisco, California, USA.
Journal:Am J Hematol. 2022 Feb 1;97(2):174-184. doi: 10.1002/ajh.26397. Epub 2021 Nov 9.

8:Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
Authors:Zeidan AM, Salimi T, Epstein RS
Institution:Section of Hematology, Department of Medicine, Yale School of Medicine & Yale Cancer Center, New Haven, CT 06511, USA. Epstein Health LLC, Woodcliff Lake, NJ 07677, USA.
Journal:Future Oncol. 2021 Dec;17(36):5163-5175. doi: 10.2217/fon-2021-0936. Epub 2021 Oct 12.

9:The wider perspective: twenty years of clinical trials in myelodysplastic syndromes.
Authors:Duetz C, Cucchi DGJ, Polak TB, Janssen JJWM, Ossenkoppele GJ, Estey EH, van de Loosdrecht AA
Institution:Department of Hematology, Amsterdam UMC, location VUmc, Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Journal:Br J Haematol. 2022 Jan;196(2):329-335. doi: 10.1111/bjh.17892. Epub 2021 Oct 10.

10:Meaningful response criteria for myelodysplastic syndromes.
Authors:Kim N, Pavletic S, Norsworthy KJ
Institution:National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Journal:Br J Haematol. 2022 Mar;196(5):1137-1148. doi: 10.1111/bjh.17838. Epub 2021 Oct 10.

11:Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape.
Authors:Schwind S, Jentzsch M, Kubasch AS, Metzeler KH, Platzbecker U
Institution:Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, Leipzig University Hospital, Leipzig, Germany. Leipzig University Hospital, Leipzig, Germany. Leipzig University Hospital, Leipzig, Germany. Leipzig University Hospital, Leipzig, Germany. Leipzig University Hospital, Leipzig, Germany; German MDS Study Group (G-MDS), Leipzig, Germany; European Myelodysplastic Syndromes Cooperative Group, Leipzig, Germany. Electronic address: uwe.platzbecker@medizin.uni-leipzig.de.
Journal:Neoplasia. 2021 Nov;23(11):1101-1109. doi: 10.1016/j.neo.2021.09.002. Epub 2021 Sep 30.

12:Novel agents for myelodysplastic syndromes.
Authors:Xu K, Hansen E
Institution:VA Central Ohio Healthcare System, Columbus, USA.
Journal:J Oncol Pharm Pract. 2021 Dec;27(8):1982-1992. doi: 10.1177/10781552211037993. Epub 2021 Sep 24.

13:Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists.
Authors:Stojkov I, Conrads-Frank A, Rochau U, Koinig KA, Arvandi M, Puntscher S, van Marrewijk C, Fenaux P, Symeonidis A, Chermat F, Garelius H, Bowen D, Mittelman M, Mora E, de Witte T, Efficace F, Siebert U, Stauder R
Institution:Institute of Public Health, Medical Decision Making, and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics, and Technology, Hall in Tirol, Austria. Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria.
Journal:Blood Adv. 2022 Jan 11;6(1):1-12. doi: 10.1182/bloodadvances.2021004568.

14:Hematopoietic stem cell transplantation for classical inherited bone marrow failure syndromes: an update.
Authors:Pierri F, Faraci M, Giardino S, Dufour C
Institution:Hematopoietic Stem Cell Transplantation Unit, Italy. Genova, Italy.
Journal:Expert Rev Hematol. 2021 Oct;14(10):911-925. doi: 10.1080/17474086.2021.1977119. Epub 2021 Sep 15.

15:The anemia-independent impact of myelodysplastic syndromes on health-related quality of life.
Authors:Wouters HJCM, Conrads-Frank A, Koinig KA, Smith A, Yu G, de Witte T, Wolffenbuttel BHR, Huls G, Siebert U, Stauder R, van der Klauw MM
Institution:Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. h.j.c.m.wouters@umcg.nl. Groningen, 9700 RB, Groningen, The Netherlands. h.j.c.m.wouters@umcg.nl. Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria. Innsbruck, Innsbruck, Austria. of York, York, UK. of York, York, UK. Netherlands. Groningen, 9700 RB, Groningen, The Netherlands. Groningen, Groningen, The Netherlands. Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria. Medicine, Innsbruck, Austria. Harvard T.H. Chan School of Public Health, Boston, MA, USA. Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Innsbruck, Innsbruck, Austria. Groningen, 9700 RB, Groningen, The Netherlands.
Journal:Ann Hematol. 2021 Dec;100(12):2921-2932. doi: 10.1007/s00277-021-04654-1. Epub 2021 Sep 2.

16:Advances in myelodysplastic syndrome.
Authors:Santini V
Institution:MDS Unit, Department of Experimental and Clinical Medicine, Hematology, AOU Careggi, University of Florence , Florence , Italy.
Journal:Curr Opin Oncol. 2021 Nov 1;33(6):681-686. doi: 10.1097/CCO.0000000000000790.

17:Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes.
Authors:Nazha A, Komrokji R, Meggendorfer M, Jia X, Radakovich N, Shreve J, Hilton CB, Nagata Y, Hamilton BK, Mukherjee S, Al Ali N, Walter W, Hutter S, Padron E, Sallman D, Kuzmanovic T, Kerr C, Adema V, Steensma DP, Dezern A, Roboz G, Garcia-Manero G, Erba H, Haferlach C, Maciejewski JP, Haferlach T, Sekeres MA
Institution:Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH. Institute, Tampa, FL. Cleveland, OH. Cleveland, OH. Cleveland, OH. Cleveland, OH. Institute, Tampa, FL. Institute, Tampa, FL. Institute, Tampa, FL. Cleveland, OH. Cleveland, OH. Cleveland, OH. School, Boston, MA. Medical College, New York, NY. TX. Cleveland, OH.
Journal:J Clin Oncol. 2021 Nov 20;39(33):3737-3746. doi: 10.1200/JCO.20.02810. Epub 2021 Aug 18.

18:Pre-transplant therapy for patients with myelodysplastic syndromes: A systematic review and meta-analysis.
Authors:Wang H, Li Y, Zhou W, Wang R, Li Y, Yu L
Institution:School of Medicine, Nankai University, Tianjin, China; Department of Hematology, Chinese PLA General Hospital, Beijing, China; Department of Hematology and Oncology, International Cancer Center, Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University Health Science Center, Shenzhen, China. Electronic address: liyu301@vip.163.com.
Journal:Leuk Res. 2021 Nov;110:106645. doi: 10.1016/j.leukres.2021.106645. Epub 2021 Jun 23.

19:What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?
Authors:Komrokji R, Al Ali N, Padron E, Lancet J, Nazha A, Steensma D, DeZern A, Roboz G, Garcia-Manero G, Sekeres MA, Sallman D
Institution:Malignant Hematology Department, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Journal:Leuk Lymphoma. 2021 Nov;62(11):2762-2767. doi: 10.1080/10428194.2021.1938028. Epub 2021 Jun 11.

20:Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.
Authors:Estey E, Hasserjian RP, Döhner H
Institution:Division of Hematology, University of Washington, Seattle, WA. Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
Journal:Blood. 2022 Jan 20;139(3):323-332. doi: 10.1182/blood.2021011304.

21:Impact of obesity on survival of patients with myelodysplastic syndromes.
Authors:Schwabkey Z, Al Ali N, Sallman D, Kuykendall A, Talati C, Sweet K, Lancet J, Padron E, Komrokji R
Institution:Hematology Department, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Journal:Hematology. 2021 Dec;26(1):393-397. doi: 10.1080/16078454.2021.1929692.

22:Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes.
Authors:Liu L, Jia M, Sun L, Tian W, Tang P, Jiang Z
Institution:Department of Hematology, First Affiliated Hospital of Zhengzhou University, 1 Jianshe East Road, Zhengzhou, 450052, China. liuliuxx1983@163.com. Jianshe East Road, Zhengzhou, 450052, China. Jianshe East Road, Zhengzhou, 450052, China. Jianshe East Road, Zhengzhou, 450052, China. Jianshe East Road, Zhengzhou, 450052, China. Jianshe East Road, Zhengzhou, 450052, China.
Journal:Clin Exp Med. 2021 Nov;21(4):537-543. doi: 10.1007/s10238-021-00712-0. Epub 2021 Apr 17.

23:Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era.
Authors:Hong S, Rybicki L, Corrigan D, Hamilton BK, Sobecks R, Kalaycio M, Gerds AT, Dean RM, Hill BT, Pohlman B, Jagadeesh D, Anwer F, Majhail NS
Institution:Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. Clinic, Cleveland, OH, USA. Cleveland, OH, USA. Cleveland, OH, USA. Cleveland, OH, USA. Cleveland, OH, USA. Cleveland, OH, USA. Cleveland, OH, USA. Cleveland, OH, USA. Cleveland, OH, USA. Cleveland, OH, USA. Cleveland, OH, USA. Cleveland, OH, USA. Electronic address: majhain@ccf.org.
Journal:Hematol Oncol Stem Cell Ther. 2021 Dec;14(4):318-326. doi: 10.1016/j.hemonc.2020.11.006. Epub 2020 Dec 5.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount


Medifocus Guidebook on Myelodysplastic Syndromes

Updated: January 3, 2022
188 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $49.95
  • Less 20% Discount = - $10.00
  • Discounted Price = $39.95(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $34.95
  • Less 20% Discount = - $7.00
  • Discounted Price = $27.95

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MS340779616

Coupon Expires: January 10, 2023



What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
P.M.
Saint Ismier, France


"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
S.M.
Rockville, Maryland


"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
N.M.
Los Angeles, California



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2022 Medifocus, Inc. All rights reserved.